Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MYOV - Myovant Sciences Ltd


Close
26.98
-0.010   -0.037%

Share volume: 0
Last Updated: Thu 09 Mar 2023 10:01:01 PM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$26.99
-0.01
-0.04%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
44%
Profitability 50%
Dept financing 25%
Liquidity 27%
Performance 47%
Company vs Stock growth
vs
Performance
5 Days
-0.04%
1 Month
0.26%
3 Months
0.15%
6 Months
54.89%
1 Year
123.47%
2 Year
28.33%
Key data
Stock price
$26.98
P/E Ratio 
0.00
DAY RANGE
$26.98 - $27.00
EPS 
$0.00
52 WEEK RANGE
$7.67 - $27.06
52 WEEK CHANGE
$1.23
MARKET CAP 
2.620 B
YIELD 
N/A
SHARES OUTSTANDING 
97.235 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,572,759
AVERAGE 30 VOLUME 
$1,097,921
Company detail
CEO:
Region: US
Website: myovant.com
Employees: 579
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Recent news